Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?

We currently favor A-18 for stage III disease (clinical or node-positive). A-18 had a more modern RT technique both for EBRT and brachytherapy while in INTERLACE, 60% had a prescription to point A for brachytherapy. In comparison with the EMBRACE 3D brachytherapy series, pelvic recurrence rate seems...

For KEYNOTE-A18, I follow the FDA label: FIGO 2014 Stage III/IV. I would welcome a more detailed review of the Stage IB2 to IIB node positive.

For INTERLACE: I have restricted my use of this regimen to patients with disease that have an enlarged volumetric disease burden.

There are several insightful editorials on this topic, including:

Lindegaard et al., PMID 38986568

Duska and Randall, PMID 39419052